Prenatal Vitamins and the Risk of Offspring Autism Spectrum Disorder: Systematic Review and Meta-Analysis

Catherine Friel 1,*, Alastair H. Leyland 1, Jana J. Anderson 2, Alexandra Havdahl 3,4,5, Tiril Borge 6, Michal Shimonovich 1 and Ruth Dundas 1

1 Medical Research Council/Chief Science Office Social and Public Health Sciences Unit, University of Glasgow, Glasgow G3 7HR, UK; alastair.leyland@glasgow.ac.uk (A.H.L.); 2405470@student.gla.ac.uk (M.S.); ruth.dundas@glasgow.ac.uk (R.D.)
2 Public Health Research Group, Institute of Health & Wellbeing, University of Glasgow, Glasgow G12 8RZ, UK; jana.anderson@glasgow.ac.uk
3 Department of Mental Disorders, Norwegian Institute of Public Health, 222 Skoyen, 0213 Oslo, Norway; alexandra.havdahl@psykologi.uio.no
4 Nic Waals Institute, Lovisenberg Diakonal Hospital, Postboks 4970 Nydalen, 0440 Oslo, Norway
5 Promenta Research Center, Department of Psychology, University of Oslo, Boks 1072 Blindern, 0316 Oslo, Norway
6 Division for Health Services, Cluster of Reviews and Health Technology Assessments, Norwegian Institute of Public Health, P.O. Box 222 Skoyen, 0213 Oslo, Norway; tiril.cecilie.borge@fhi.no
* Correspondence: c.friel.1@research.gla.ac.uk

Abstract: Prenatal nutrition is associated with offspring autism spectrum disorder (herein referred to as autism), yet, it remains unknown if the association is causal. Triangulation may improve causal inference by integrating the results of conventional multivariate regression with several alternative approaches that have unrelated sources of bias. We systematically reviewed the literature on the relationship between prenatal multivitamin supplements and offspring autism, and evidence for the causal approaches applied. Six databases were searched up to 8 June 2020, by which time we had screened 1309 titles/abstracts, and retained 12 articles. Quality assessment was guided using Newcastle–Ottawa in individual studies, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) for the body of evidence. The effect estimates from multivariate regression were meta-analysed in a random effects model and causal approaches were narratively synthesised. The meta-analysis of prenatal multivitamin supplements involved 904,947 children (8159 cases), and in the overall analysis showed no robust association with offspring autism; however, a reduced risk was observed in the subgroup of high-quality observational studies (RR 0.77, 95% CI (0.62, 0.96), $I^2 = 62.4%$), early pregnancy (RR 0.76, 95% CI (0.58; 0.99), $I^2 = 79.8%$) and prospective studies (RR 0.69, 95% CI (0.48, 1.00), $I^2 = 95.9%$). The quality of evidence was very low, and triangulation was of limited utility because alternative methods were used infrequently and often not robustly applied.

Keywords: autism spectrum disorder; folic acid; maternal nutrition; meta-analysis; multivitamin; systematic review

1. Introduction

Autism spectrum disorder (hereafter “autism”) is a neurodevelopmental condition characterised by early-onset impairment in social communication and restricted and repetitive behaviour [1]. Prenatal nutrition may be a modifiable risk factor, which creates a potential target for prevention strategies and may reduce the significant public health implications of this condition. Autism in the U.K. is estimated to cost GBP 27 billion (EUR 29.8 billion) annually for health, education, and social care and in lost productivity [2] despite a modest prevalence of around 1.5% [3].
Previous reviews and meta-analysis reported a reduced risk of offspring autism associated with prenatal folic acid (FA) or multivitamin supplements [4,5], but as the conventional rhetoric states: “correlation does not imply causation”. The conditions necessary for estimating causality are greatly debated, and although randomised controlled trials are considered to be the gold-standard, their utility in nutritional epidemiology is limited because of ethical, financial, and practical barriers. For example, as the prevalence of autism is only 1.5%, a large sample size is necessary for adequate statistical power, but acquiring one is financially burdensome [6]. Conversely, a causal inference from non-experimental studies is problematic, largely due to bias [7]. For example, individuals may overreport compliance with prenatal nutritional supplements, creating a misclassification bias, or confounders, which influence both the exposure and outcome, create a spurious association.

Aetiological triangulation recognises that all approaches have bias and then exploits unrelated sources of bias to “test” the consistency of results [7]. Causal inferences are strengthened if we have consistent results across multiple approaches with different sources of bias, as the bias may vary across different study designs, methods or analytical approaches. Some examples include conventional multivariate regression, gene-nutrient interactions, discordant sibling studies, cross-context comparisons and negative controls (see Lawlor et al. for an overview of approaches in triangulation [7]). We used the term “alternative causal approaches” to refer to the abovementioned approaches that are alternatives to conventional multivariate regression.

Evidence from alternative causal approaches is unsystematically synthesised in previous reviews, if at all, which limits transparency. As alternative causal approaches are increasingly applied within studies and may significantly alter causal reasoning, this evidence should be integrated in an explicit and scientifically rigorous process. This aligns with guidance from Cochrane [8] and a recent guideline on systematic aetiological reviews of observational studies [9]. We first reviewed the overall evidence from studies using conventional multivariate regression to investigate the association between prenatal nutritional status and autism in offspring. Second, we narratively synthesised the causal approaches. Lastly, we updated the search and addressed the limitations of previous reviews such as double-counting individual studies [5,10], or using the DerSimonian and Laird estimator, which can underestimate uncertainty [4,5].

2. Materials and Methods

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were followed [11] (Supplementary Table S1). The review protocol was registered on the Prospective Register of Systematic Reviews, registration number: CRD42019154613. Available online: https://www.crd.york.ac.uk/prospero (accessed on 23 July 2021).

2.1. Inclusion and Exclusion Criteria

The study designs were trials, cohort, case-controls and cross-sectional studies of any duration. We focused on the use of folic acid and multivitamin supplements (hereafter simply “multivitamin supplement”) in women during preconception and prenatal periods because folic acid is generally sourced from a multivitamin supplement [4]. Comparators were high versus low or no supplement intake. The outcome was offspring autism diagnosis based on the Diagnostic and Statistical Manual of Mental Disorders, International Classification of Disease, and health registers. There were no date limitations, but non-English language and animal studies were excluded.

2.2. Study Identification and Selection

The search strategy and selection of databases were guided by an information scientist with expertise in systematic reviews. Search strategies were adapted to each database. The following databases were searched from the earliest date to 8 June 2020; MEDLINE
Table 1. Search strategy for MEDLINE (OVID).

| Search String | Search Terms |
|---------------|--------------|
| Population    | (Pregnancy OR Fetal development OR Prenatal).af. OR Fetal development/OR “fetal development”.af. OR “fetal programing”.af OR “fetal programing”.af |
| Exposure      | NUTRITIONAL PHYSIOLOGICAL PHENOMENA OR Prenatal Nutritional Physiological Phenomena/OR Maternal nutritional physiological phenomena/OR DIET OR nutri* OR vitamin OR diet* OR mineral OR Nutritional Status |

An asterisk (*) is used as truncation in Medline and allows any word ending.

Titles and abstracts were screened, full articles reviewed, and quality assessment was completed twice independently for each study, by C.F., T.B., and M.S. Disagreements were resolved through discussion and adjudicated, by J.A. Data were extracted by C.F. using a standardised form comprised of, author, year of publication, country and cohort, study design, sample size, age of participants, nutritional supplement, measure of autism, covariates, results, and causal approach.

2.3. Quality Assessment

The Newcastle–Ottawa Scale guided the quality assessment of each observational study. Scores range from 0 to 9, where a score of 7–9 was considered high quality in the subgroup analysis and consistent with similar previous reviews [5,12]. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the body of evidence based on the degree of certainty in the result [8].

2.4. Data Synthesis and Analysis

We narratively synthesised studies that were inappropriate to meta-analysis. Additionally, we summarised the alternative approaches applied in table format.

2.5. Meta-Analysis

We conducted a meta-analysis of the fully adjusted effect estimates in a random effects model using the Hartung–Knapp–Sidik–Jonkman estimator [8]. Analyses of nutritional supplements were pooled if the exposure was categorical: no or low supplement intake as the reference category compared against supplement use. Autism is a rare outcome, so we assumed the odds ratio (OR) and hazard ratio (HR) were directly comparable to the relative risk (RR) [13]. The heterogeneity was measured with the Cochrane’s q and I² statistics. The interpretation of heterogeneity (I²) was guided by Cochrane’s reference ranges [8]. Prediction intervals estimated the range of effect estimates that may be expected in individual settings that could improve the application of the research findings. These are distinct from the summary effect and 95% confidence intervals (CIs) that estimate the average effect of the exposure [8,14,15]. The R version 3.6.3 packages used were “meta” and “forestplots” [16]. Statistical tests of significance were 2-sided with an α of 0.05.

2.6. Sensitivity Analysis

Sources of heterogeneity were explored through the identification of outliers, leave-one-out analysis and subgroup analysis if there were ≥10 studies. A random effects model was used to estimate between and within subgroup effects. The pre-defined subgroups were study quality, study design (prospective/retrospective), region, mandatory fortification (yes/no), and stage of pregnancy, which was defined as the first trimester, compared against any point in pregnancy, if the nutritional supplement exposure period was undefined. Between-subgroup differences were measured with the q statistic and significance was indicated by p < 0.1 (2-sided). Small-study publication bias was assessed through the
inspection of the funnel plot and Egger’s test [17]. The widely used DerSimonian and Laird estimator may underestimate uncertainty [8], but to facilitate comparison with previous research, we applied it in sensitivity analyses.

3. Results

3.1. Identification of Studies

A total of 1309 titles were identified with 342 duplicates, leaving 967 titles and abstracts to be screened (Figure 1). Of these, 897 were excluded based on title and abstract review, leaving 70 for a full-text review, of which 13 met the inclusion criteria. However, two reports were duplicated [18,19], and so the larger cohort was retained [19] leaving 12 studies in the final review, 10 of which were meta-analysed. The other two were narratively synthesised because the reference category was not low or no supplement use [20,21].

3.2. Quality Assessment

Based on the Newcastle–Ottawa Scale, five [20,22–25] of seven cohort studies [19,20,22–26] were of high quality, and two [27,28] of five case-control studies [21,27–30] were of high quality (Supplementary Tables S2 and S3). The quality of the body of evidence based on GRADE was very low (Table 2). The details for the evidence profile and rationale for GRADE rating are provided in Supplementary Tables S4 and S5. For a summary of studies and results, see Table 3.
3.3. Meta-Analytic Results

A total of 904,947 children including 8159 cases from six countries were included in the meta-analysis. All studies measured nutritional supplements and one included fortified food. The multivitamin dose was seldom reported.

Overall, there was no robust evidence to associate taking prenatal multivitamins with autism risk compared to no/low intakes (RR 0.74, 95% CI: 0.53, 1.04) (Figure 2). The confidence intervals (CI) were wide, and there was considerable heterogeneity ($I^2 = 94.3\%$, $p < 0.001$). Egger’s test ($p = 0.44$) and inspection of the funnel plot suggests no evidence of asymmetry (Supplementary Figure S1). The precision increased when the DerSimonian and Laird estimator was applied compared to the Hartung–Knapp–Sidik–Jonkman estimator (RR 0.74, 95% CI: 0.57, 0.95, $I^2 = 94.3\%$). Upon removal of the outlier, DeSoto and Hitlan, there was a 32% reduced risk of autism (RR 0.68, 95% CI: 0.51, 0.91, $I^2 = 94.7\%$, $p < 0.001$); although heterogeneity remained considerable. There were no other influential studies (Supplementary Table S7). The 95% prediction interval indicated that the dispersion in the distribution of effect estimates was large and ranged from a reduced to an increased risk of autism (RR 0.21, 2.59).

Subgroup Analysis

See Supplementary Figures S2–S6. In high-quality observational studies there was a 23% reduced risk of autism associated with maternal multivitamin use, and heterogeneity was reduced from considerable to substantial (RR 0.77, 95% CI: 0.62, 0.96, $I^2 = 62.4\%$). No association was observed in low-quality studies (RR 0.78, 95% CI: 0.33, 1.86, $I^2 = 97.9\%$), and there were no between-subgroup differences detected ($Q = 0.00$, $p = 0.98$). Some evidence of association was observed in prospective studies (RR 0.69, 95% CI: 0.48, 1.00, $I^2 = 95.9\%$), whilst no association was evident in the retrospective studies (RR 0.93, 95% CI: 0.41, 2.11, $I^2 = 81.7\%$). There were no differences between subgroups for study design ($Q = 0.42$, $p = 0.51$). Subgroup analysis of regions reduced heterogeneity from “considerable” in Nordic (RR 0.87, 95% CI: 0.72, 1.06, $I^2 = 76.8\%$) and American (RR 0.87, 95% CI: 0.5, 2.15, $I^2 = 84.5\%$) studies. Asian countries had the largest effect estimate, but there was considerable heterogeneity (RR 0.56, 95% CI: 0.26, 1.23, $I^2 = 97.1\%$). No differences between subgroups were detected ($Q = 1.14$, $p = 0.57$). Subgroup analysis of the stage of pregnancy showed similar effect estimates in each group (early pregnancy: RR 0.76, 95% CI: 0.58, 0.99, $I^2 = 79.8\%$; any stage of pregnancy: RR 0.78, 95% CI: 0.40, 1.53, $I^2 = 96.6\%$). There were no between-subgroup differences ($Q = 0.01$, $p = 0.93$). Regions without mandatory fortification produced a stronger reduction in the risk of autism (RR 0.71, CI 95%: 0.50, 1.02, $I^2 = 96\%$), compared to regions with mandatory fortification (RR 0.87, CI 95%: 0.35, 2.15, $I^2 = 84\%$). There were no between-subgroup differences detected ($Q = 1.14$, $p = 0.57$).

Table 2. Summary of GRADE evaluation.

| Study               | Cases/Total Sample | RR   | 95% CI  | Quality of Evidence (GRADE) |
|---------------------|--------------------|------|---------|-----------------------------|
| 7 cohort/5 case-control | 8761/1,025,534     | 0.74 | 0.53, 1.04 | very low                   |
Table 3. Study characteristics and results from individual studies [19–30].

| Author/Study Design | Country/Cohort/Sample | Exposure Measure(s) | Outcome Measure | Covariates<sup>*</sup> | Results Effect Size Estimate and 95% CI |
|---------------------|-----------------------|---------------------|-----------------|-------------------------|----------------------------------------|
| Desoto and Hitlan, 2012 [29]/case-control | USA 256 cases and 752 controls, age range 6–12 years | Self-reported FA or multivitamin supplement use obtained from health records | ICD-9 | Child: anaemia, pica, sex, birth weight, birth order, year of birth, breast feeding, sex and FA interaction<br>Maternal: age, poverty ratio, adequacy of prenatal care, cholesterol screen, pamp smear, prenatal alcohol use, prenatal viral infections, lead exposure | Reference, no supplement use FA/multivitamin<br>HR 2.34 1.14, 4.82 |
| DeVilbiss et al., 2017 [22]/population-based cohort and sibling case control | Sweden/Stockholm youth cohort 273,107/1064 cases age range 4–15 years | Self-reported multivitamin supplement use recorded by midwife at first booking | DSM-IV or ICD-10 | Child: sex, birth year, and years of residence in Stockholm County<br>Maternal: country of birth, maternal education, disposable family income, age, parity, smoking, BMI at first antenatal visit, neurologic or psychiatric conditions before the child’s birth (anxiety disorders, autism, bipolar disorder, depression, intellectual disability, non-affective psychosis, stress related disorders, epilepsy), antiepileptics and antidepressants medication<br>Sibling analysis<br>child sex and birth year, maternal parity | Reference, no supplement use Multivitamin<br>OR 0.89 0.82, 0.97<br>Sibling analysis, multivitamin<br>OR 0.95 0.81, 1.13<br>Propensity score matching<br>OR 0.86 0.78, 0.95 |
| Levine et al., 2018 [26]/nested case-control | Israel/Meuhedet population based register 572 cases and 45,300 controls average age 10 years (SD 1.4) | Pharmacy records, Multivitamins and/or FA supplements | ICD-9 | Child: sex, birth year<br>Maternal: parity, socioeconomic status (high vs low), psychiatric diagnosis by childbirth, age<br>Paternal psychiatric diagnosis, age | Reference, no supplement use FA/multivitamins<br>RR 0.27 0.22, 0.33<br>Negative control| |
| Li et al., 2018 [30]/case control | China/Autism clinical and environmental database 354 cases and 374 controls, average age 4.5 years | Self-reported FA supplements | DSM-IV-TR | Child: age, premature birth, gender<br>Maternal: pre-pregnancy BMI preconception and predelivery, mode of delivery<br>Parental: age, education<br>Dietary patterns were additionally adjusted for other dietary patterns<br>FA and calcium supplements: were additionally adjusted for other supplements | Reference, no supplement use FA<br>OR 0.64 0.41, 1.00 |
| Moser et al., 2019 [27]/nested case-control | Israeli/Maccabi Healthcare Services 2009 cases and 19,886 controls | Dispensing records for FA with or without multivitamins supplements | DSM, version unreported | Child: sex, birth year, birth order<br>Maternal: age, region of residence, poverty index, number of physician visits, diabetes mellitus, hypertension, cardiovascular disease, cancer, subfertility, epilepsy, antifolate medication (progynon, methotrexate, sulfasalazine, sulphanamethoxazole and trimethoprim, pyrimethamine, valproate, carbamazepine, phenytoin and phenobarbital)<br>Final model adjusted for; maternal age, subfertility, number of physician visits, birth order, parity | Reference, ≤0.2 mg/day<br>FA supplement<br>0.2–<0.4 mg/day<br>OR 1.15 0.98, 1.24<br>0.4–<1 mg/day<br>OR 1.10 0.98, 1.24<br><1 mg/day<br>OR 1.14 0.98, 1.34<br>≥3 mg/day<br>OR 1.01 0.60, 1.70 |
Table 3. Cont.

| Author/Study Design | Country/Cohort/Sample | Exposure Measure (S) | Outcome Measure | Covariates a | Results |
|---------------------|-----------------------|----------------------|-----------------|--------------|---------|
| Raghavan et al., 2018 [20]/prospective cohort | USA/Boston Medical Centre 1257/86 cases, aged up to 9 year | Self-reported maternal multivitamin supplement use | ICD-9 | Maternal; homocysteine, race, age, smoking status, diabetes, reduction, parity, MTHFR 677 genotype, BMI | Reference, multivitamins 2–5 times/week  
First trimester ≤ 2/week  
HR 3.4 1.6, 7.2  
HR 2.3 1.2, 3.9  
Second trimester ≤ 2/week  
HR 3.8 1.8, 8.0  
HR 2.1 1.2, 3.6  
Third trimester ≤ 2/week  
HR 3.5 1.7, 7.4  
HR 2.1 1.2, 3.6 |
| Schmidt et al., 2019 [23]/prospective cohort | USA/Markers of Autism Risk in Babies: Learning Early Signs (MARBLES) 332/55 cases, average age 36.5 months | Self-reported multivitamin supplement use obtained through three telephone interviews | Autism Diagnostic Observation Schedule and DSM-5 | Child; birthplace, sex, year of birth  
Maternal; education, age, pre-pregnancy BMI, planned pregnancy, race/ethnicity, home ownership, insurance delivery type.  
Paternal; age  
Covariates in final model, maternal characteristics (education, age, insurance delivery type) and child characteristics (race) | Reference, no supplement use Multivitamin RR 0.50 |
| Schmidt et al 2012 [25]/case control | USA/Childhood autism risks from genetics and environment (CHARGE) 429 cases and 278 controls age range 24–60 months | Self-reported obtained FA intake based on supplements, including multivitamin supplements, and fortified breakfast cereals, shakes and bars obtained via telephone interview | Health records and Autism Diagnostic Interview–Revised and the Autism Diagnostic Observation Schedule–Generic | Child; birth year, sex, race  
Maternal; race, age, education, pre-pregnancy BMI, birthplace, residing with a smoker, smoking status, alcohol consumption, other nutrients intakes (calcium, iron, vitamin A, B12, C, D and E)  
Preeclampsia, type of delivery, vaginal bleeding during pregnancy, induced labour  
Paternal: age  
Covariates in final model; childbirth year and maternal education | Reference, no supplement use  
All strata combined OR 0.62 0.42, 0.92  
Strata by C/T genotypes maternal CC OR 1.20 0.61, 2.34  
maternal CT/TT OR 0.46 0.25, 0.85  
child CC OR 1.15 0.55, 2.38  
child CT/TT OR 0.48 0.27, 0.88  
both mother & child OR 1.29 0.54, 3.10  
either mother or child CT/TT OR 0.49 0.16, 1.50  
both mother and child CT/TT OR 0.30 0.10, 0.90 |
Table 3. Cont.

| Author/Study Design | Country/Cohort/Sample | Exposure Measure (S) | Outcome Measure | Covariates * | Results |
|---------------------|------------------------|----------------------|-----------------|-------------|---------|
| Suren et al., 2013 [24]/prospective cohort | Norway/Norwegian mother, father and child cohort (MoBa) 85,176/114 cases, mean age of 6.4 years | Self-reported questionnaire responses, multivitamin and mineral supplement, FA supplement | DSM-IV or ICD-10 | Child; birth year Maternal; planned pregnancy, smoking, BMI, parity, weight gain at 18 and 30 weeks Parental; education, age Covariates retained in final model; birth year, parity and maternal education | Reference, no supplement use FA/multivitamins OR 0.61 0.41, 0.90 Negative control Reference, no fish oils supplements Fish oil supplements OR 1.29 0.88, 1.89 |
| Strom et al., 2017 [19]/prospective cohort | Denmark/Danish National Birth Cohort 87,210/1234 cases, age range 11–17 years | Self-reported folate/FA, vitamin and mineral supplement use, reported during GP interview | ICD-10 | Child; sex Maternal; age, parity, smoking, education, socioeconomic status (based on occupation and education), planned pregnancy, pre-pregnancy BMI Paternal; age | Reference, no supplement use FA/multivitamins HR 1.06 0.94, 1.19 |
| Tan et al., 2020 [21]/case-control | China 416 cases and 201 control mean age 4.68 years cases, 4.47 years controls | Self-reported FA or micronutrient supplements | DSM-5 | Child; age, sex, gestational age, birth weight Maternal; residence (rural/urban), labour mode Paternal; age Household; income | Reference, supplement use No FA supplements 1.91 1.24, 2.93 No micronutrient supplements 1.72 1.20, 2.47 |
| Nilsen et al., 2013 [25]/population based cohort | Norway/Norwegian registry 507,856/2072 cases, mean age 7 years | Self-reported FA intake obtained via maternal health records | ICD-10 | Child; birth year Maternal; age, marital status, parity, hospital size Paternal; age | Reference, no supplement use FA OR 0.86 0.78, 0.95 |

* All covariates initially considered relevant by the authors are listed as well as the final selection. Initialisms: BMI, Body Mass Index; DSM, Diagnostic and Statistical Manual of Mental Disorders; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders Text Revision; FA, folic acid; GDM, gestational diabetes mellitus; GWG, gestational weight gain; ICD, International Classification of Disease; SD standard deviation; MTHFR 677, Methlyenetetrahydrofolate reductase 677 (genotype); CT/TT/CC, genotype variants; Q, Quintle; SNP, single-nucleotide polymorphism.
Figure 2. Forest plot of maternal multivitamin supplements and risk of offspring autism [19,21–28,30].

3.4. Causal Approaches

All studies [19,22–30] measured the association between prenatal nutrition and autism using conventional multivariate regression. Alternative causal approaches (one discordant sibling analysis, two negative controls studies, and one genetic interaction study) were infrequently applied (Table 4) and were generally used as a secondary analysis to conventional multivariate regression. A detailed summary of the key sources of bias in each approach can be read in Supplementary Table S6.

Table 4. Summary of causal approaches which demonstrates multivariate regression was commonly applied whilst all other approaches were infrequently used.

| Study                      | Design          | Sample Size Cases/Children (Cases) | Multivariate Regression/GEE | Causal Diagram | Propensity Score | Sibling Study | Negative Control | Genetic Studies |
|----------------------------|-----------------|-----------------------------------|-----------------------------|----------------|------------------|---------------|------------------|-----------------|
| **Folic acid/multivitamins** |                 |                                    |                             |                |                  |               |                  |                 |
| Desoto and Hitlan, 2012    | Case-control    | 256/752                           | ▼                           |                |                  |               |                  |                 |
| DeVilbiss et al., 2017     | Cohort          | 273,107 (1064)                    | ▲                           | ▲              | ▲                | Δ             |                  |                 |
| Levine et al., 2018        | Cohort          | 45,300 (572)                      | ▲                           |                |                  |               |                  |                 |
| Li et al., 2018            | Case-control    | 354/374                           | ▲                           |                |                  |               |                  |                 |
| Moser et al., 2019         | Case-control    | 2009/19,886                       | △                           |                |                  |               |                  |                 |
| Nilsen et al., 2013        | Cohort          | 507,856 (2072)                    | ▲                           |                |                  |               |                  |                 |
| Raghavan et al., 2017 a    | Cohort          | 1257 (86)                         | ▼                           |                |                  |               |                  |                 |

\(^a\) Taking supplements twice/week or taking supplements > five times/week.
Table 4. Cont.

| Study                        | Design      | Sample Size   | Multivariate Regression/GEE | Causal Diagram | Propensity Score | Sibling Study | Negative Control | Genetic Studies |
|------------------------------|-------------|---------------|-----------------------------|----------------|------------------|---------------|------------------|-----------------|
| Schmidt et al., 2019         | Cohort      | 241 (55)      | ▲                           |                |                  |               |                  |                 |
| (taking supplements)         |             |               |                             |                |                  |               |                  |                 |
| Schmidt et al., 2012         | Case-control| 429/278       | ▲                           |                |                  |               | ▲ c              |                 |
| (taking supplements)         |             |               |                             |                |                  |               |                  |                 |
| Suren et al., 2013           | Cohort      | 85,176 (114)  | ▲                           |                |                  |               | ▽ d              |                 |
| (taking supplements)         |             |               |                             |                |                  |               |                  |                 |
| Strom et al., 2017           | Cohort      | 87,210 (1234) | ▽                           |                |                  |               |                  |                 |
| (taking supplements)         |             |               |                             |                |                  |               |                  |                 |
| Tan et al., 2020 (not        | Case-control| 416/201       | ▲                           |                |                  |               |                  |                 |
| taking supplements)          |             |               |                             |                |                  |               |                  |                 |

Effect direction: ▲ indicates a positive health impact, ▽ indicates a negative health impact. Significance association indicated with a black arrow, no association is indicated with an unshaded arrow (△, ▽); The nutrient source is supplements/fortified food (reference group: no/low intake); a Raghavan et al. reference group is 3–5/week compared to low and high supplements intakes; △ negative control was two years pre-pregnancy and had a stronger association with autism; △ Beneficial effects of folic acid supplements were only detected if the child or mother had at least one T allele which reduces the efficiency of folate metabolism; △ negative control was fish oils, which showed no association with autism.

4. Discussion

Prenatal multivitamin supplements were not robustly associated with autism in the overall meta-analysis. However, a reduced risk of autism was observed in high-quality studies, prospective studies, early pregnancy and following the removal of an outlier. In contrast with previous meta-analyses, we did not observe any strong evidence of association in our main results (using all studies) due to the selection of the Hartung–Knapp–Sidik–Jonkman estimator, rather than DerSimonian–Laird which underestimates uncertainty and was applied in previous meta-analysis [4,5,31]. We also identified an additional two studies [21,27]. However, although some associations were identified, based on GRADE the degree of certainty was very low owing to the inherent risk of bias in observational study designs, considerable heterogeneity, and unexplained inconsistency in the direction of effect. As GRADE does not easily incorporate alternative causal approaches [32], we structured the discussion first to discuss the limitations identified through the application of GRADE. Second, we evaluated whether the alternative causal methods had been of value to the interpretation of causality.

Regional variation in baseline nutritional status and genotype [5,33] may be major contributors to both heterogeneity and inconsistency in the direction of the effect. Nutrients confer a benefit to health until physiological requirements are satisfied; thereafter, we observe a plateau effect, and toxicity or deficiency occurs when intakes are extreme [34]. To illustrate this potential U-shaped relationship, we considered baseline folate status. Studies in this review from Nordic countries generally showed effect estimates closest to the null, except Norway [24,25]. The Nordic associations correlated with rates of plasma folate deficiency/insufficiency, which were reported to be 0.7% in Denmark [35], 4% in Sweden [36], but 24.9% in a subsample of the Norwegian mother, father and child cohort [37]. However, the comparisons between supplement use and plasma folate levels were drawn from different populations, and population heterogeneity and confounding may have caused variance at the individual level. Future studies should consider the response to nutritional supplements in relation to baseline nutritional status.
Furthermore, from the reviewed studies, only the U.S. implements mandatory fortification of diet with folic acid and so has a high baseline folic acid intake. Less than 1% of its population has had deficient plasma folate levels since the introduction of mandatory fortification in 1998 [38], but this may have reduced the benefits from supplements since physiological requirements are already met. However, a plateau effect was not observed. Instead, two U.S. studies found a reduced risk of autism associated with multivitamin supplements [23,28], and two studies observed an increased risk of autism [20,29]. There is much uncertainty and debate as to whether toxicity could occur through the combined effects of mandatory fortification and supplementation with folic acid [39]. Wiens and DeSoto (2017) argued that excessive intake saturates metabolic pathways, leading to an accumulation of unmetabolized folic acid which may cause autism [39]. Furthermore, folic acid is absorbed more readily than the folate form and is used in supplements and fortified food which the authors argued further exacerbates excessive intake. However, other research groups found inconclusive evidence to support such claims, even though limitations in available evidence were acknowledged [40].

The two studies in this review that observed a reduced risk of autism had folic acid intakes well in excess of the recommended 400 ug/day [23,28], yet they focused on early pregnancy when, it is speculated, folic acid requirements and tolerance to high doses is greater. An alternative explanation for the increased risk of autism is “birth order bias” [41]. Autism and supplement use can be positively correlated independently, as supplement use is usually greater in first pregnancies, and families affected by autism have fewer children. Indeed, an increased risk of autism in Moser et al. was attenuated to the null with restrictions to first-born boys [27].

An additional source of heterogeneity is variation in the stage of pregnancy when the multivitamin supplement was taken. In early pregnancy it was associated with a lower risk of autism and lower heterogeneity. Periconception is an established critical period in which FA can reduce the incidence of neural tube defects by up to 70% [42]. Furthermore, FA in periconception may reduce the risk of low birth weight, small gestational age size, stillbirth, neonatal mortality, preeclampsia and miscarriage [42].

Lastly, autism is a heterogeneous condition and specific features might have differential causal pathways [43], which may contribute to varied results. All studies that stratified by severity, observed a greater magnitude of association with more severe forms of autism [21,22,24,26] as defined by minimal verbal status at age 3 [24], low intelligence quotient [22,26], or high autism symptom severity [21].

4.1. Alternative Causal Approaches

4.1.1. Multivariate Regression

Alternative causal approaches were infrequently applied, and the application was often not robust; therefore, our ability to triangulate the findings was limited. All studies used multivariate regression, a key assumption of which is no residual confounding [7]. However, there was such a risk in this review as studies were adjusted for many, but seldom all, key confounders. The studies commonly adjusted for maternal age, physical or mental health, socioeconomic status, parity, planned pregnancy, pre-pregnancy BMI, and health behaviour. Due to the risk of residual confounding we attempted to triangulate the results from the multivariate regression with alternative approaches that have different sources of bias. However, only the gene-nutrient interaction analysis provided useful results.

4.1.2. Gene-Nutrient Interaction

In Schmidt et al., an association between folate use and autism risk was only observed if the mother/child had the methylenetetrahydrofolate reductase (MTHFR) 677 C > T genotype, which is unlikely owing to confounding by socioeconomic and lifestyle characteristics [28]. The MTHFR 677 C > T genotype encodes for a less-efficient enzyme to metabolise folate. Hence, larger folate doses may be necessary to overcome inefficient enzy-
matic function [28]. Although these findings are yet to be replicated in larger samples, there is consistency in the wider literature. A recent meta-analysis identified an 86% increased risk of autism associated with the less-efficient genotype (TT genotype verses CC genotype: OR 1.86, 95% CI: 1.12, 2.18) [44]. Furthermore, this association was not evident in countries that had a higher intake of folic acid secondary to mandatory folic acid fortification. This may imply that a genotype influences the response to supplements or mandatory folic acid fortification.

4.1.3. Discordant Sibling Analysis

Discordant sibling analyses may overcome shared unmeasured confounding despite several key methodological considerations. In DeVilbiss et al., the reduced risk of autism observed in their main analysis was attenuated by the discordant sibling analysis [22]. Sibling comparison studies are a quasi-experimental study design intended to remove shared familial confounding by matching siblings discordant for the outcome. However, this includes shared genetic risk factors [7], and siblings share, on average, 50% of their genetic material. As indicated in Schmidt et al.’s study, it may be the combination of MTHFR 677 C > T genotype and no folic acid supplements that led to an increased risk of autism. Thus, this sibling comparison may have adjusted for a causal component. Furthermore, there is a high type II error rate as only siblings discordant for the exposure and outcome contribute to the effect estimate in conditional logistic regression models [45]. DeVilbiss et al.’s discordant sibling analysis may be underpowered because the confidence intervals were wider even though the point estimate was consistent with the main analysis. Furthermore, random error can be amplified in discordant sibling analysis and bias towards the null. Conversely, time-varying confounders should be adjusted as matching on siblings does not account for this [45]. Thus, the null association observed here should be interpreted with caution as it could reflect a type II error or adjustment for a causal component, MTHFR genotype.

4.1.4. Negative Control

In two studies, negative controls were applied and acted as mock exposures that indicate the presence of bias without relying on the assumption of no unmeasured confounding [46]. Instead, they depend on the assumption that confounding, and sometimes other biases, were similar in exposure and negative control analyses. A further assumption was that the negative control had no plausible relationship with the outcome. Therefore, the exposure–outcome relationship could be distinguished from bias by comparing the strength of the association with the negative control analysis [7], but the assumptions were empirically untestable. Thus, we were limited to a subjective interpretation based on subject knowledge [46] which is presented here.

Suren et al. measured an association with multivitamin supplements, but not fish oils [24] even though they are a rich source of polyunsaturated fatty acids, especially omega-3s, and cod liver oil is a rich source of vitamin D, both of which are associated with positive neurodevelopmental outcomes [47,48]. Conversely, cod liver oil is a rich source of vitamin A which is potentially teratogenic and can harm foetal development [49]. Thus, this negative control violates the assumption of no plausible relationship with the outcome, which confused the interpretation. Similarly, Levine et al.’s negative control may have had a relationship with the exposure. The authors compared mutually exclusive groups for multivitamins: two years prior to pregnancy, two years prior to pregnancy and during pregnancy, and during pregnancy only. All groups were associated with a reduced risk of autism, yet the association was strongest and most similar for “two years prior to pregnancy” and “two years prior to pregnancy and during pregnancy”. No “wash-out” period was used, so two years prior to pregnancy may have included the potentially critical period, preconception. Furthermore, the assumption of similar bias may not be met either since women who discontinue supplements during pregnancy may have different
characteristics to women who adhere to health advise and take the supplements during pregnancy. Thus, we lacked confidence in this negative control.

4.1.5. Triangulation

Collectively, triangulation as a strategy to further causal interpretation was limited, many due to infrequent use and limitations in applying alternative approaches. The multivariate regression and gene-nutrient interaction [24] findings suggest there could have been a causal association, and we feel this warrants further investigation. However, within the context of this review, the discordant sibling analysis [22] and negative control analyses [24,26] were of limited utility. The former needs to be conducted on larger samples and adjusted for a range of time-varying confounders, and the choice of the latter should be given careful consideration.

4.2. Strengths and Limitations

This review has several strengths. Numerous steps to reduce bias were taken, such as searching grey literature sources, applying GRADE guidelines, calculating prediction intervals and using the Hartung–Knapp–Sidik–Jonkman estimator. However, the strongest advance was a formal narrative synthesis of the range of causal approaches. As an explicit approach, it provided transparent evidence of the approaches applied, their findings and outlined areas for future studies. Nonetheless, there were weaknesses, mainly the heterogeneity and inconsistency observed across studies and the low study numbers. The prediction intervals indicated if there had been an effect, it could have ranged from beneficial to null or even harmful in individual settings.

5. Conclusions

At present, the evidence is inconclusive, and we are unable to confirm a causal association between prenatal multivitamin supplement use and autism in offspring. Future studies should improve the study design and data analyses through adequately powered prospective birth cohorts. The measurement of nutritional supplements could be improved through reporting their nutrient composition, dose, compliance and duration and timing of use, which are all known to affect biological responses but were rarely considered in the studies we reviewed. Furthermore, there should be greater consideration of the complexity of nutrition by modelling U-shaped relationships and considering how the response to nutrients is altered by variations in baseline requirements and whether it is affected by recent nutrient intake, changes to physiological demand in early pregnancy, or genetic variation. Lastly, we recommend the application of alternative approaches within a triangulation framework to gauge causality better.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/nu13082558/s1, Figure S1: Multivitamins: funnel plot, Figure S2: Multivitamin subgroup analysis by study quality, Figure S3: Multivitamin subgroup analysis by study design, Figure S4: Multivitamin subgroup analysis by region, Figure S5: Multivitamins subgroup analysis by stage of pregnancy, Figure S6: Multivitamins subgroup analysis by mandatory fortification. Table S1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses, Table S2: Quality assessment using the Newcastle Ottawa Scale: case-control, Table S3: Quality assessment using the Newcastle Ottawa Scale: cohort, Table S4: GRADE evidence profile, Table S5: Optimal information size, Table S6: Summary of the key sources of bias for each causal approach, Table S7: Influential study analysis.

**Author Contributions:** C.F. was the lead author and the led all stages, including conceptualisation, methodology, formal analysis, and all stages of writing. Additionally, R.D., A.H.L. and J.J.A. provided supervision of the conceptualisation, methodology, formal analysis, and writing—review and editing. They also reviewed and critically revised the article for intellectual content. Furthermore, J.J.A. contributed to the formal data analysis by acting as adjudicator to resolve disputes over study inclusion. A.H. assisted with the methodology and formal analysis and writing—review and editing. T.B. assisted in the screening of titles and abstracts, full-text reviews and quality assessment; and writing—review and editing. M.S. assisted in the screening of titles and abstracts, full-text reviews and quality assessment.
and quality assessment; and writing—review and editing. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Medical Research Council (MC_UU_00022/2 to R.D., C.F. and A.H.L., and 304823-02 to C.F.); the Scottish Government Chief Scientist Office (SPHSU17 to R.D., C.F. and A.H.L.); and the University of Glasgow (MC_ST_U18004 to M.S.). A.H. was supported by a career grant from the South-Eastern Norway Regional Health Authority (2018059 and 2020022).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Available on request.

**Acknowledgments:** We thank Valerie Wells for her expertise in information science and her support in devising the search strategy.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. World Health Organization. *International Classification of Diseases and Related Health Problems;* 11th rev., ICD-11; World Health Organization: Geneva, Switzerland, 2020.

2. Knapp, M.; Romeo, R.; Beecham, J. Economic cost of autism in the UK. *Autism* 2009, 13, 317–336. [CrossRef]

3. Lyall, K.; Croen, L.; Daniels, J.; Fallin, M.D.; Ladd-Acosta, C.; Lee, B.K.; Park, B.Y.; Snyder, N.W.; Schendel, D.; Volk, H.; et al. The Changing Epidemiology of Autism Spectrum Disorders. *Annu. Rev. Public Health* 2017, 38, 81–102. [CrossRef]

4. Li, M.; Francis, E.; Hinkle, S.N.; Ajjarapu, A.S.; Zhang, C. Preconception and Prenatal Nutrition and Neurodevelopmental Disorders: A Systematic Review and Meta-Analysis. *Nutrients* 2019, 11, 1628. [CrossRef]

5. Guo, B.Q.; Li, H.-B.; Zhai, D.-S.; Ding, S.-B. Maternal multivitamin supplementation is associated with a reduced risk of autism spectrum disorder in children: A systematic review and meta-analysis. *Nutr. Res.* 2019, 65, 4–16. [CrossRef]

6. Kendall, J.M. Designing a research project: Randomised controlled trials and their principles. *Emerg. Med. J.* 2003, 20, 164–168. [CrossRef]

7. Lawlor, D.A.; Tilling, K.; Smith, G.D. Triangulation in aetiological epidemiology. *Int. J. Epidemiol.* 2016, 45, 1866–1886. [CrossRef]

8. Higgins, J.P.T.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. (Eds.) *Cochrane Handbook for Systematic Reviews of Interventions*, 2nd ed.; John Wiley & Sons: Chichester, UK, 2019.

9. Dekkers, O.M.; Vandenbroucke, J.P.; Cevallos, M.; Renehan, A.G.; Altman, D.G.; Egger, M. COSMOS-E: Guidance on conducting systematic reviews and meta-analyses of observational studies of etiology. *PLoS Med.* 2019, 16, e1002742. [CrossRef]

10. Guo, B.Q.; Li, H.B.; Zhai, D.S.; Ding, S.B. Association of maternal prenatal folic acid intake with subsequent risk of autism spectrum disorder in children: A systematic review and meta-analysis. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 2019, 94, 109650. [CrossRef] [PubMed]

11. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Grp, P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *Int. J. Surg.* 2010, 8, 336–341. [CrossRef] [PubMed]

12. Wang, M.; Li, K.; Zhao, D.; Li, L. The association between maternal use of folic acid supplements during pregnancy and risk of autism spectrum disorders in children: A meta-analysis. *Mol. Autism* 2017, 8, 1–4. [CrossRef]

13. McKenzie, D.P.; Thomas, C. Relative risks and odds ratios: Simple rules on when and how to use them. *Eur. J. Clin. Investig.* 2020, 50, e13249. [CrossRef] [PubMed]

14. Riley, R.D.; Higgins, J.P.; Deeks, J.J. Interpretation of random effects meta-analyses. *BMJ* 2011, 342, d549. [CrossRef] [PubMed]

15. IntHout, J.; Ioannidis, J.P.A.; Rovers, M.M.; Goeman, J.J. Plea for routinely presenting prediction intervals in meta-analysis. *BMJ Open.* 2016, 6, e010247. [CrossRef]

16. Gordon, M.; Lumley, T. Advanced Forest Plot Using ‘grid’ Graphics, December 12, 2020. R Package Version 1.10 ed.: CRAN. Available online: https://cran.r-project.org/web/packages/forestplot/forestplot.pdf (accessed on 23 July 2021).

17. Duval, S.; Tweedie, R. Trim and Fill: A Simple Funnel-Plot-Based Method of Testing and Adjusting for Publication Bias in Meta-Analysis. *Biometrics* 2000, 56, 455–463. [CrossRef] [PubMed]

18. Virk, J.; Liew, Z.; Olsen, J.; Nohr, E.A.; Catov, J.M.; Ritz, B. Preconceptional and Prenatal Supplementation of Folic Acid and Multivitamins and Autism Spectrum Disorders. *Autism* 2016, 20, 710–718. [CrossRef] [PubMed]

19. Strøm, M.; Granström, C.; Lyall, K.; Ascherio, A.; Olsen, S.F. Research letter: Folic acid supplementation and intake of folate in pregnancy in relation to offspring risk of autism spectrum disorder. *Psychol. Med.* 2018, 48, 1048–1054. [CrossRef]

20. Raghavan, R.; Riley, A.W.; Volk, H.; Caruso, D.; Hironaka, L.; Sikes, L.; Hong, H.; Wang, G.; Ji, Y.; Brucato, M.; et al. Maternal Multivitamin Intake, Plasma Folate and Vitamin B12 Levels and Autism Spectrum Disorder Risk in Offspring. *Paediatr. Perinat. Epidemiol.* 2018, 32, 100–111. [CrossRef]

21. Tan, M.; Yang, T.; Zhu, J.; Li, Q.; Lai, X.; Li, Y.; Tang, T.; Chen, J.; Li, T. Maternal folic acid and micronutrient supplementation is associated with vitamin levels and symptoms in children with autism spectrum disorders. *Reprod. Toxicol.* 2020, 91, 109–115. [CrossRef]
22. DeVilbiss, E.A.; Magnussen, C.; Gardner, R.M.; Rai, D.; Newschaffer, C.J.; Lyall, K.; Dalman, C.; Lee, B.K. Antenatal nutritional supplementation and autism spectrum disorders in the Stockholm youth cohort: Population based cohort study. *Br. Med. J.* 2017, 359, J4273. [CrossRef]

23. Schmidt, R.J.; Josif, A.-M.; Angel, E.G.; Ozonoff, S. Association of Maternal Prenatal Vitamin Use With Risk for Autism Spectrum Disorder Recurrence in Young Siblings. *JAMA Psychiatry* 2019, 76, 391–398. [CrossRef]

24. Suren, P.; Roth, C.; Bresnahan, M.; Haugen, M.; Hornig, M.; Hirtz, D.; Lie, K.K.; Lipkin, W.I.; Mangus, P.; Reichborn-Kjennerud, T.; et al. Association Between Maternal Use of Folic Acid Supplements and Risk of Autism Spectrum Disorders in Children. *JAMA J. Am. Med. Assoc.* 2019, 320, 570–577. [CrossRef]

25. Nilsen, R.M.; Gunnes, N.; Alsaker, E.R.; Bresnahan, M.; Hirtz, D.; Hornig, M.; Lie, K.K.; Lipkin, W.I.; Mangus, P.; Reichborn-Kjennerud, T.; et al. Analysis of self-selection bias in a population-based cohort study of autism spectrum disorders. *Paediatr. Perinat. Epidemiol.* 2013, 27, 553–563. [CrossRef]

26. Levine, S.Z.; Kodesh, A.; Viktorin, A.; Smith, L.; Uher, R.; Reichenberg, A.; Sadin, S. Association of Maternal Use of Folic Acid and Multivitamin Supplements in the Periods Before and During Pregnancy with the Risk of Autism Spectrum Disorder in Offspring. *JAMA Psychiatry* 2018, 75, 176–184. [CrossRef]

27. Moser, S.S.; Davidovitch, M.; Rotem, R.S.; Chadick, G.; Shalev, V.; Koren, G. High dose folic acid during pregnancy and the risk of autism; The birth order bias: A nested case-control study. *Reprod. Toxicol.* 2019, 89, 173–177. [CrossRef]

28. Schmidt, R.J.; Tancredi, D.J.; Ozonoff, S.; Hansen, R.L.; Hartilia, J.; Allayee, H.; Schmidt, L.C.; Tassone, F.; Hertz-Picciotto, I. Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (Childhood Autism Risks from Genetics and Environment) case-control study. *Am. J. Clin. Nutr.* 2012, 96, 80–89. [CrossRef] [PubMed]

29. Desoto, M.C.; Hitlan, R.T. Synthetic folic acid supplementation during pregnancy may increase the risk of developing autism. *J. Pediatr. Biochem.* 2012, 2, 251–261.

30. Li, Y.-M.; Shen, Y.-D.; Li, Y.-J.; Xun, G.-L.; Liu, H.; Wu, R.-R.; Xia, K.; Zhao, J.-P.; Ou, J.-J. Maternal dietary patterns, supplements intake and autism spectrum disorders A preliminary case-control study. *Medicine* 2018, 97, e13902. [CrossRef]

31. Iglesias Vazquez, L.; Canals, J.; Arija, V. Review and meta-analysis found that prenatal folic acid was associated with a 58% reduction in autism but had no effect on mental and motor development. *Acta Paediatr. Int. J. Paediatr.* 2019, 108, 600–610. [CrossRef]

32. Guyatt, G.H.; Oxman, A.D.; Sultan, S.; Glasziou, P.; Akl, E.A.; Alonso-Coello, P.; Atkins, D.; Kunz, R.; Brozek, J.; Montori, V.; et al. GRADE guidelines: 9. Rating up the quality of evidence. *J. Clin. Epidemiol.* 2011, 64, 1311–1316. [CrossRef]

33. Virk, J.; Liew, Z.; Olsen, J.; Nohr, E.A.; Catov, J.M.; Ritz, B. Pre-conceptual and prenatal supplementary folic acid and multivitamin intake, behavioral problems, and hyperkinetic disorders: A study based on the Danish National Birth Cohort (DNBC). *Nutr. Neurosci.* 2018, 21, 352–360. [CrossRef]

34. Scientific Committee on Food, Scientific Panel on Dietetic Products Nutrition and Allergies. *Tolerable Upper Intake Levels for Vitamins and Minerals;* European Food Safety Authority: Parma, Italy, 2006.

35. Milman, N.; Byg, K.E.; Hvas, A.M.; Bergholt, T.; Eriksen, L. Erythrocyte folate, plasma folate and plasma homocysteine during normal pregnancy and postpartum: A longitudinal study comprising 404 Danish women. *Eur. J. Haematol.* 2006, 76, 200–205. [CrossRef]

36. Ohrvik, V.; Lemming, E.W.; Nilsen, C.; Becker, W.; Ridefelt, P.; Lindroos, A.K. Dietary intake and biomarker status of folate in Swedish adults. *Eur. J. Nutr.* 2018, 57, 451–462. [CrossRef] [PubMed]

37. Nilsen, R.M.; Vollset, S.E.; Monsen, A.L.; Ulvik, A.; Haugen, M.; Meltzer, H.M.; Magnus, P.; Ueland, P.M. Infant birth size is not associated with maternal intake and status of folate during the second trimester in Norwegian pregnant women. *J. Nutr. Epidemiol.* 2010, 140, 572–579. [CrossRef]

38. Pfeiffer, C.M.; Hughes, J.P.; Lacher, D.A.; Bailey, R.L.; Berry, R.J.; Zhang, M.; Yetley, E.A.; Rader, J.I.; Sempos, C.T.; Johnson, C.L.; et al. Estimation of trends in serum and RBC folate in the US population from pre- to postfortification using assay-adj usted data from the NHANES 1988–2010. *J. Nutr.* 2012, 142, 886–893. [CrossRef] [PubMed]

39. Wiens, D.; DeSoto, M.C. Is High Folic Acid Intake a Risk Factor for Autism?—A Review. *Brain Sci.* 2017, 7, 149. [CrossRef] [PubMed]

40. Scientific Advisory Committee on Nutrition (SACN). *Folic Acid: Updated SACN Recommendations;* Public Health England: London, UK, 2017.

41. Koren, G.; Moser, S.S. Does high-dose gestational folic acid increase the risk for autism? The birth order hypothesis. *Med. Hypotheses* 2019, 132, 109350. [CrossRef]

42. Stephenson, J.H.N.; Hall, J.; Schoenaker, D.A.J.M.; Hutchinson, J.; Cade, J.E.; Poston, L.; Barrett, G.; Crozier, S.R.; Barker, M.; Kumaran, K.; et al. Before the beginning: Nutrition and lifestyle in the preconception period and its importance for future health. *Lancet* 2018, 391, 1830–1841. [CrossRef]

43. Whitehouse, A.J.O.; Stanley, F.J. Is autism one or multiple disorders? *Med. J. Aust.* 2013, 198, 3. [CrossRef] [PubMed]

44. Pu, D.; Shen, Y.; Wu, J. Association between MTHFR Gene Polymorphisms and the Risk of Autism Spectrum Disorders: A Meta-Analysis. *Autism Res.* 2015, 6, 384–392. [CrossRef]

45. Frisell, T.; Öberg, S.; Kuja-Halkola, R.; Sjölander, A. Sibling Comparison Designs Bias from Non-Shared Confounders and Measurement Error. *Epidemiology* 2012, 23, 713–720. [CrossRef]
46. Shi, X.; Miao, W.; Tchetgen, E.T.A. A Selective Review of Negative Control Methods in Epidemiology. *Curr. Epidemiol. Rep.* 2020, 7, 190–202. [CrossRef]

47. Lyall, K.; Munger, K.L.; O’Reilly, E.J.; Santangelo, S.L.; Ascherio, A. Maternal Dietary Fat Intake in Association With Autism Spectrum Disorders. *Am. J. Epidemiol.* 2013, 178, 209–220. [CrossRef] [PubMed]

48. Wu, D.M. Relationship between Neonatal Vitamin D at Birth and Risk of Autism Spectrum Disorders: The NBSIB Study. *J. Bone Miner. Res.* 2018, 33, 458–466. [CrossRef] [PubMed]

49. World Health Organization. *WHO Recommendations on Antenatal Care for a Positive Pregnancy Experience;* World Health Organization: Geneva, Switzerland, 2016.